2 results
Approved WMOWill not start
To determine the performance of CardioFit* for the treatment of Class II-IV Heart Failure patients with preserved left ventricular function
Approved WMOCompleted
Primary Objective:• To assess and compare efficacy of sacituzumab govitecan to TPC as measured by progression free survival (PFS) as determined by blinded independent central review (BICR) using Response Evaluation Criteria in Solid Tumors Version 1…